The results of late-stage clinical trials are scrutinised as never before, and even products that surmount safety and efficacy requirements must overcome increasingly challenging pharmacoeconomic and medical outcome hurdles.

The high cost of new cancer therapies has made them targets for critical analysis. The rewards may be great for patients and companies alike, but successfully bringing a new product to market is a complex, difficult-to-predict business.

Tracking and evaluating these new products through their late-stage development is essential and that is why both industry and the investment community will value this comprehensive new service from one of the world's leading providers of oncology business data. Tykerb (lapatinib) GlaxoSmithKline
Following priority review, lapatinib was approved for the US market in March 2007 for the treatment of patients with advanced or metastatic breast cancer in combination with Xeloda (capecitabine) in women who have received prior therapy, including Herceptin (trastuzumab). Filings for first-line treatment are also expected, as are registrational studies in lung and other cancers. CRITICAL EVALUATION OF THE PRODUCT'S PROSPECTS ARE PROVIDED Espicom's New Cancer Drug Tracker reports will inform you and your colleagues of the essential details of a new product's prospects and keep you up to date. When new information is sourced by editors the two-year development tracker is updated along with any adjustment to the forecasts and estimates. Changes to the data are highlighted on the front page of the report allowing you to instantly see the latest information. When a significant event happens the entire report is sent to you again so that the forecasts and evaluations can be reviewed in the light of the latest developments. Updates are sent for 12 months.